No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
OGN Organon & Co
- 17.820
- -0.040-0.22%
Close Apr 19 16:00 ET
- 17.810
- -0.010-0.06%
Post 19:54 ET
4.56BMarket Cap4.47P/E (TTM)
18.025High17.380Low3.61MVolume17.880Open17.860Pre Close64.18MTurnover1.42%Turnover Ratio4.47P/E (Static)255.64MShares23.21452wk High-65.04P/B4.54BFloat Cap10.67152wk Low1.12Dividend TTM254.87MShs Float35.537Historical High6.29%Div YieldTTM3.61%Amplitude10.671Historical Low17.768Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | NYSE Order Imbalance 142150.0 Shares on Sell Side 142150.0 Shares on Sell Side
Express News | NYSE Order Imbalance 90051.0 Shares on Sell Side
CVS Favors Humira Copycats Hurting AbbVie's Market Share: Evercore
Express News | NYSE Order Imbalance 190519.0 Shares on Sell Side
Unafraid of generic drugs entering the US market, ABBV.US (ABBV.US) Humira still accounts for nearly 100% of the share
Although a large number of discounted biosimilars entered the US market more than a year ago, ABBV.US (ABBV.US)'s blockbuster arthritis drug Humira (adalimumab) continues to maintain nearly 100% of the market share.
Play Safe! S&P 500 Is Teasingly Close to Its 50 DMA: 3 Picks
Comments
Organon's low P/E ratio is due to its predicted growth being less than the broader market. Shareholders accept this as they anticipate future earnings won't bring any pleasant surprises. The share price is unlikely to rise significantly soon under these conditions.
Organon & Co.'s (NYSE:OGN) Earnings Are Not Doing Enough For Some Investors 1
Analysts show increased negativity towards the business following recent results, reflected in a minor decrease in next year's EPS estimates. Despite predicted earnings decline, Organon's valuation is not expected to be significantly affected, but growth is anticipated to lag behind the industry.
1
Seeking Alpha analysts are growing more bullish on the Merck spinoff, despite Wall Street's neutral stance. Analysts Leo Nelissen and Gen Alpha highlight OGN's attractive yield as a reason for their Buy ratings.
1
Despite the company's payout ratio not posing an immediate concern, the significant decline in earnings per share raises concerns about Organon from a dividend perspective. Therefore, caution is advised for potential investors considering Organon for its upcoming dividend.
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg